文献速递肿瘤 PET/CT

18F-FDG PET/CT预测乳腺癌患者新辅助全身治疗后腋窝病理完全缓解的价值:强调乳腺癌亚型

Value of 18F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype.
PubMed 文献 · EJNMMI Res · 2021-11-22

本研究纳入66例患者共69个原发肿瘤,评估基线18F-FDG PET/CT预测新辅助全身治疗后腋窝病理完全缓解的价值。在ER阳性/HER2阴性亚型中,PET参数在腋窝残留病灶与病理完全缓解者间无显著差异;在HER2阳性/三阴性合并亚组中,无腋窝残留病灶者的SUVmax显著较低,腋窝最FDG高摄取淋巴结SUVmax截断值4.89可预测腋窝残留病灶,敏感度90%、特异度69%、PPV 53%、NPV 95%。

要点

  • ER阳性/HER2阴性乳腺癌中,PET参数与腋窝病理完全缓解无显著关联。
  • HER2阳性/三阴性合并亚组中,无腋窝残留病灶者SUVmax显著较低。
  • 腋窝最FDG高摄取淋巴结SUVmax截断值4.89预测腋窝残留病灶的NPV为95%。

核心结论

  • 聚焦乳腺癌亚型时,基线18F-FDG PET/CT可用于预测新辅助全身治疗后的腋窝反应。
  • 易计算的PET参数SUVmax可预测HER2阳性和三阴性乳腺癌的腋窝反应。
  • 本研究补充了累积证据,提示探讨18F-FDG PET/CT在乳腺癌中价值的研究应始终考虑亚型。

研究设计与样本

  • 本研究纳入66例患者共69个原发肿瘤,在基线18F-FDG PET/CT上测量原发肿瘤及最FDG高摄取腋窝淋巴结的PET参数。
  • 影像学总体发现与腋窝手术标本组织病理学金标准进行比较。
  • ER阳性/HER2阴性分析与HER2阳性及三阴性患者分开进行,并对临床淋巴结阳性患者另行分析。

主要发现

  • 33个腋窝为ER阳性/HER2阴性乳腺癌,16个为HER2阳性,20个为三阴性乳腺癌。
  • ER阳性/HER2阴性乳腺癌中,腋窝残留病灶患者与腋窝病理完全缓解患者间PET参数无显著差异。
  • HER2阳性/三阴性合并亚组中,无腋窝残留病灶患者SUVmax显著较低,整个队列及临床淋巴结阳性患者中均如此。
  • 该合并亚组中,腋窝最FDG高摄取淋巴结SUVmax截断值4.89预测腋窝残留病灶的敏感度90%、特异度69%、PPV 53%、NPV 95%。

关键数值与推荐

  • 腋窝最FDG高摄取淋巴结SUVmax截断值4.89预测腋窝残留病灶:敏感度90%、特异度69%、PPV 53%、NPV 95%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant systemic therapy (NST) is a widely accepted initial treatment modality that can lead to pathologic downstaging of the axillary disease burden in breast cancer patients. Axillary response as well as baseline 18F-fluorodeoxyglucose (18F-FDG) uptake on positron emission tomography with computed tomography (PET/CT) differ between breast cancer subtypes. The value of baseline 18F-FDG PET/CT in predicting axillary response to NST is not yet established, possibly since breast cancer subtype was not taken into account. The purpose of this study was to investigate the value of baseline 18F-FDG PET/CT in predicting axillary response to NST with a specific emphasis on subtype. METHODS: PET-parameters derived from the primary tumor as well as the most FDG-avid axillary lymph node were measured on baseline 18F-FDG PET/CT. Overall imaging findings were compared with the gold standard of histopathology of the axillary surgery specimen. Analyses for ER-positive/HER2-negative were performed separately from HER2-positive and TN patients. In addition, separate analyses for clinically node-positive patients were performed. RESULTS: Sixty-six patients with 69 primary tumors were included in this study. Thirty-three axillae contained ER-positive/HER2-negative, 16 HER2-positive, and 20 TN breast cancer. No significant difference in PET-parameters between patients with axillary residual disease and axillary pathologic complete response were found for ER-positive/HER2-negative breast cancer. In the combined HER2-positive/TN subgroup, the SUVmax was significantly lower in patients without residual axillary disease in both the entire cohort and in patients with clinically node-positive disease. In this combined subgroup, a cut-off of 4.89 SUVmax measured on the most FDG-avid axillary lymph node could predict residual axillary disease with a sensitivity, specificity, PPV, and NPV of 90%, 69%, 53%, and 95%, respectively. CONCLUSIONS: Predicting axillary response following NST with baseline 18F-FDG PET/CT can be performed when focusing on breast cancer subtypes. The easily computed PET-parameter SUVmax can predict axillary response in HER2-positive and TN breast cancer. This study adds to the accumulating evidence that studies investigating the value of 18F-FDG PET/CT in breast cancer should always take subtypes into account.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. de Mooij CM, Mitea C, Mottaghy FM, et al. Value of 18F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype. EJNMMI Res. 2021. PMID: 34807395. doi:10.1186/s13550-021-00861-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。